[Yonhap Photo]
Candidates for remedies listed by the Ministry of Food and Drug Safety included camostat mesilate, ciclesonide, clevudine, nafamostat mesilate, ifenprodil, EC-18 (synthetic monoacetyldiglyceride), pyronaridine phosphate/Artesunate, and baricitinib sold under the brand name of Olumiant.
The two vaccines are GX-19, a DNA vaccine material developed by Genexine, a clinical-stage biotechnology company in South Korea, and INO-4800 developed by Inovio Pharmaceuticals, an American biotechnology company.
Genexine is involved in joint vaccine research in Indonesia, Thailand and Turkey. South Korea has unveiled a roadmap for the treatment of COVID-19 to develop plasma treatment by the year's end as well as antibody treatment and vaccines next year.
Copyright ⓒ Aju Press All rights reserved.
Related News
-
United States Loses Measles Elimination Status for First Time in 26 Years
The United States has lost its measles elimination status for the first time in 26 years.According to the BBC, the Pan American Health Organization (PAHO), a branch of the World Health Organization (WHO), announced on the 17th (local time) that the same type of measles virus has been continuously transmitted in the U.S. for over 12 months, resulting in the revocation of the country's elimination status. Mexico and Bolivia have also lost their status.This year alone, the U.S. has reported 5,400 measles cases and 10 deaths, marking the largest outbreak since the 1990s. In Pennsylvania, a single outbreak infected more than 1,400 people and resulted in seven deaths. Jarbas Barbosa, PAHO's director, warned that "measles is spreading globally again amid ongoing gaps in vaccination."A decline in vaccination rates is cited as a contributing factor. The vaccination rate for the measles, mumps, and rubella (MMR) vaccine in the U.S. stands at 92.4%, below the 95% threshold needed for herd immunity. An assistant professor at Columbia University Irving Medical Center described the situation as a "massive setback," noting that misinformation about vaccines has eroded trust in the healthcare system since the COVID-19 pandemic, according to the BBC.The BBC also reported that the medical community views misinformation from Health and Human Services Secretary Robert F. Kennedy Jr. and President Donald Trump as major causes of the decline in vaccination rates. Vaccine skeptic Secretary Kennedy has frequently questioned the safety of the MMR vaccine, while President Trump issued an executive order this year to administer the MMR vaccine in three separate doses.Kennedy also countered that the increase in cases began before his appointment, but he continues to advocate for MMR vaccination as the most effective way to prevent measles on social media. The Centers for Disease Control and Prevention (CDC) stated that it aims to restore elimination status by expanding vaccine accessibility.Countries that lose their elimination status must submit corrective plans to PAHO that include measures to increase vaccination rates. This year, several European countries, including the United Kingdom, Spain, and Austria, also lost their measles-free status.* This article has been translated by AI.
-
GC Biopharma teams up with Dongbang FTL on homegrown LNP lipids
SEOUL, November 17 (AJP) - GC Biopharma said Tuesday it has signed an agreement with DongBang Future Tech & Life, a pharmaceutical ingredients maker, to explore domestic production of ionizable lipids, a key material in mRNA vaccines. The memorandum of understanding signed Monday, concerns of Ionizable lipids, which are a component of lipid nanoparticles (LNP) that protect fragile mRNA and deliver it into cells. GC Biopharma has filed patents on 12 LNP designs built on its own lipid library: eight high-expression types and four targeted types. The company has been buying lipid materials through overseas contract research organizations. It expects the partnership to give it a domestic lipid library and speed up its screening of promising candidates. In 2022, GC Biopharma signed a development and option agreement with Canada’s Acuitas Therapeutics, the LNP developer whose technology went into Pfizer and BioNTech’s COVID-19 vaccine. Tags: GC Biopharma, DongBang Future Tech & Life, Pfizer, BioNTech, Acuitas Therapeutics, COVID-19 vaccine
-
Government Overhauls Livestock Disease Prevention System with Focus on Proactive Measures
The government will flexibly apply livestock culling and movement restrictions based on the characteristics and risks of infectious diseases. It plans to enhance farmer self-inspections and increase compensation benefits for exemplary farms, shifting the focus of the disease prevention system to proactive measures.On November 3, the Ministry of Agriculture, Food and Rural Affairs announced the 'K-Livestock Disease Prevention Improvement Plan' to address new patterns of disease transmission and risk factors. This plan is structured around three main strategies: proactive prevention and field capacity enhancement, improving response effectiveness during outbreaks, and reforming the disease management system.◆ Expanding Farmer Self-Inspections and Introducing Certification System in 2027To enhance farmers' self-inspection capabilities, the government will shift from government-led inspections to farmer self-inspections. Farmers will verify their biosecurity status using a checklist, while the government will focus on inspecting farms that have not been checked, randomly selected farms, and high-risk farms.Smart and artificial intelligence (AI) technologies will be introduced in five key biosecurity areas, including farm disinfection, access control, and disease detection. Data from farms, control posts, and disinfection facilities will be linked to the National Livestock Disease Prevention Integrated System (KAHIS) for real-time risk response.Starting in 2027, a certification system for disease management exemplary farms will be introduced. Clean certified farms and well-managed farms will be selected among egg-laying hens, breeding pig farms, and large-scale pig farms, receiving incentives such as support for biosecurity materials and reduced compensation deductions. Consulting services will be provided to farms with weak biosecurity capabilities.The scope of biosecurity training will also expand from farm owners to farm managers and employees. A multilingual training program will be offered to foreign workers from entry to farm work. The government will also promote the development of domestic vaccines through public-private partnerships. A foot-and-mouth disease platform vaccine is expected to be commercialized by 2027, along with the development of vaccines and diagnostic methods for highly pathogenic avian influenza (AI). The development of an African swine fever (ASF) vaccine is planned for completion by 2030.◆ Differentiated Application of Livestock Culling and Movement Restrictions Based on RiskIn the event of an outbreak of livestock infectious diseases, the response will be tailored based on the characteristics and transmission risks of each disease. For foot-and-mouth disease, the government will utilize the cattle traceability system and KAHIS to identify and manage animals that have missed vaccination. Pre-vaccination and vaccine stockpiling will be implemented in high-risk areas in anticipation of the new SAT1 strain emerging from neighboring countries. The goal is to secure 32 million doses of the SAT1 vaccine by 2027, with 10 million doses stockpiled by the end of this year.For ASF, the government will focus on managing key transmission risk factors such as wild boars, illegal livestock distribution, and plasma protein feed. For highly pathogenic AI, a pre-registration system for personnel and vehicles will be introduced at egg-laying farms, which have historically experienced high outbreaks, along with tailored biosecurity programs for densely populated areas. Vaccination will be administered to high-risk farms for lumpy skin disease, and emergency pest control will be conducted through specialized companies.Culling and movement restriction measures will also be applied flexibly based on risk levels. If foot-and-mouth disease occurs in a farm that has been vaccinated and shows no clinical symptoms, partial culling may be permitted. Farms that received pigs from an ASF-affected farm will undergo precise inspections and risk assessments to potentially defer culling. Movement restrictions and temporary movement cessation orders will be applied according to the outbreak area, livestock type, and risk level.◆ Increasing Compensation Cap to 90% and Reforming Disease Management SystemThe criteria for compensation payments to farmers will also be improved. The maximum compensation for livestock infectious diseases will be raised from 80% to 90%, with farms that report outbreaks first in their regions eligible for up to 100%. The reduction rate for compensation for exemplary farms will be expanded from 10% to 15%. These changes will be reflected in the revised Livestock Infectious Disease Prevention Act, which is set to take effect in April 2027.To address the shortage of biosecurity personnel, collaboration with private veterinarians will be expanded. Livestock disease prevention officers will focus on specialized tasks such as diagnosis, surveillance, and response to new infectious diseases, while farm inspections, vaccinations, and disinfections will be shared with the private sector. The authority to appoint public veterinarians will be expanded from local to provincial levels, and retired veterinary public officials will also be utilized.Additionally, the existing livestock infectious disease prevention law, which has focused on post-outbreak responses, will be completely restructured to emphasize proactive prevention and risk management. The current classification system for livestock infectious diseases, divided into categories 1, 2, and 3, will be revised to focus on emergency management, key management, and routine management based on risk levels. A registration and evaluation system for private biosecurity industries, such as livestock waste disposal and biosecurity consulting, will also be established.Lee Sang-woo, director of the Ministry of Agriculture, Food and Rural Affairs' Biosecurity Policy Bureau, stated, "This plan will enhance the proactive prevention capabilities of relevant agencies and farmers, addressing gaps in biosecurity to effectively respond to the changing disease prevention environment. We will strive for the economic stability of livestock farmers and the stable supply of livestock products."* This article has been translated by AI.